Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Total Liabilities (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Total Liabilities data on record, last reported at $71.2 million in Q4 2025.

  • For Q4 2025, Total Liabilities fell 27.04% year-over-year to $71.2 million; the TTM value through Dec 2025 reached $71.2 million, down 27.04%, while the annual FY2025 figure was $71.2 million, 27.04% down from the prior year.
  • Total Liabilities reached $71.2 million in Q4 2025 per TRDA's latest filing, down from $72.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $287.1 million in Q2 2023 and bottomed at $39.3 million in Q1 2022.
  • Average Total Liabilities over 4 years is $129.0 million, with a median of $84.9 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: soared 619.88% in 2023, then crashed 71.34% in 2025.
  • A 4-year view of Total Liabilities shows it stood at $39.5 million in 2022, then surged by 474.23% to $226.8 million in 2023, then plummeted by 56.95% to $97.6 million in 2024, then fell by 27.04% to $71.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $71.2 million in Q4 2025, $72.2 million in Q3 2025, and $69.3 million in Q2 2025.